Celgene
VerifiedGlobal biopharmaceutical company committed to improving the lives of patients worldwide
Financials
Edit| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E |
|---|---|---|---|---|---|---|---|
| Revenues | - | 11.8b | 13.9b | - | - | - | - |
| % growth | - | - | 18 % | - | - | - | - |
| EBITDA | - | 5.4b | 5.6b | - | - | - | - |
| % EBITDA margin | - | 46 % | 40 % | - | - | - | - |
| Profit | - | 2.7b | 3.7b | - | - | - | - |
| % profit margin | - | 23 % | 26 % | - | - | - | - |
| R&D budget | 4.2b | 3.3b | 4.0b | - | - | - | - |
| R&D % of revenue | - | 28 % | 29 % | - | - | - | - |
Source: Company fillings or news article
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - Not yet verified | |
| N/A | N/A | IPO | |
* | $74.0b | Acquisition | |
| Total Funding | - | ||
Recent News about Celgene
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
Investments by Celgene
Edit
ACQUISITION by Eli Lilly May 2018
exited
ACQUISITION by Adaptive Biotechnologies Jan 2015
ACQUISITION by Celgene Jan 2018
exited
exited
exited
ACQUISITION by Ipsen Jun 2022
ACQUISITION by Celgene Dec 2009